5-Amino-1MQ for Weight Loss: What the Evidence Actually Shows

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme involved in cellular energy metabolism. Despite being sold on the same grey-market “peptide” and biohacker sites as compounds like BPC-157 and marketed for fat loss and muscle, it is not a peptide at all — it is a synthetic small molecule. The mechanism is genuinely interesting: in mouse studies, inhibiting NNMT in fat tissue raised intracellular NAD+ and SAM, suppressed fat-cell lipogenesis, and reduced body weight and white-fat mass in diet-induced-obese animals^[3]. But the honest evidence picture is short and unambiguous: there are no human trials of 5-Amino-1MQ of any kind — zero human safety data, zero human efficacy data — it is not FDA-approved, and it is sold as an unregulated “research chemical.” We verified the absence of any human trial directly in PubMed. This article explains what 5-Amino-1MQ actually is, what the mouse mechanism does and does not show, why “NNMT inhibitor for fat loss” remains an unproven hypothesis in people, the regulatory reality of buying it, and what FDA-approved obesity drugs with real human trials look like by comparison. This is an evidence review and safety caution — not a dosing or how-to-buy guide.

The honest summary

• It is not actually a peptide. 5-Amino-1MQ is a small-molecule NNMT inhibitor (a methylquinolinium compound), not a peptide. It is grouped with peptides only because it is sold through the same grey-market channels and marketed the same way.
• The mechanism is real — in mice. Inhibiting NNMT in fat tissue raised cellular NAD+ and SAM, suppressed lipogenesis in adipocytes, and reduced body weight, white-fat mass, and fat-cell size in diet-induced-obese mice, without changing food intake^[3]. Later mouse work has continued to find that NNMT inhibition improves obesity-related metabolic dysfunction^[5].
• There are no human trials at all. A targeted PubMed search for a human clinical trial of 5-Amino-1MQ (5-amino-1-methylquinolinium) returns zero results, and no published human study reports weight or fat loss as an outcome for the compound. There is no published human safety or efficacy data.
• It is not FDA-approved. 5-Amino-1MQ is not an approved drug for weight loss or for any other human indication, and it is not listed in DailyMed. It is sold “for research use only.”
• It is an unverified grey-market product. Sold as a research chemical, the identity, purity, and dose of what is actually in the bottle are not verified by any agency. “Promising in mice” is not the same as “safe and effective in people.”
• Real obesity drugs look completely different. Semaglutide and tirzepatide each have large Phase-3 human randomized trials behind them (mean weight loss of about −14.9% and up to −20.9% respectively)^[1][2]. That is the evidentiary bar 5-Amino-1MQ has not begun to clear.

What 5-Amino-1MQ actually is

5-Amino-1MQ is shorthand for 5-amino-1-methylquinolinium, a small synthetic molecule built on a methylquinolinium scaffold. Its target is an enzyme called nicotinamide N-methyltransferase (NNMT), which lives in the cell’s cytoplasm and is especially abundant in fat (adipose) tissue and liver. NNMT uses a methyl group from S-adenosyl-methionine (SAM) to convert nicotinamide — a form of vitamin B3 and a precursor of NAD+ — into a waste product called 1-methylnicotinamide (1-MNA). By blocking NNMT, 5-Amino-1MQ is designed to slow that drain on the cell’s nicotinamide and SAM pools, nudging energy metabolism in fat cells. Crucially, none of this makes it a peptide. Peptides are short chains of amino acids; 5-Amino-1MQ is a single small organic molecule. The peptide label is purely a marketing artifact of the channels that sell it.

The mouse mechanism: what the science actually shows

The foundational study is Neelakantan and colleagues, published in Biochemical Pharmacology in 2018^[3]. The team tested a series of small-molecule NNMT inhibitors built on the methylquinolinium scaffold — the chemical family that 5-Amino-1MQ belongs to. In cultured fat cells, the inhibitors lowered intracellular 1-MNA, raised NAD+ and SAM, and suppressed lipogenesis (the building of new fat). When a potent NNMT inhibitor was given to diet-induced-obese mice on a high-fat diet, the animals showed a significant reduction in body weight and white-adipose mass, smaller fat cells, and lower plasma cholesterol — notably without any change in total food intake and with no observable adverse effects in that study. The authors framed NNMT as a plausible anti-obesity drug target and pointed to increased flux of NAD+ and SAM as the likely mechanism.

That core finding has held up in subsequent rodent and cell work. A 2024 study in Diabetes, Obesity and Metabolism reported that NNMT inhibition mitigated obesity-related metabolic dysfunction^[5], and earlier mechanistic work showed that glucose availability regulates NNMT expression in adipocytes — tying the enzyme to nutrient state^[6]. There is even a mouse study combining NNMT inhibition with a reduced-calorie diet, which found the combination shaped a distinct gut microbiome in diet-induced-obese mice^[4]. Taken together, these papers make NNMT a legitimately interesting metabolic target. What they do not do is establish anything about 5-Amino-1MQ in humans.

Why there is no human evidence — and what that means

We searched PubMed for a human clinical trial of 5-amino-1-methylquinolinium and found none, and no published human study reports weight or fat loss as an outcome for 5-Amino-1MQ. This is not a citation we are choosing to leave out — it is an absence in the literature itself. For a YMYL (your-money-or-your-life) health claim, that absence is the finding. “No proof of harm” is not “proof of safety,” and “reduces fat in mice” is not “works in people.” The compound has not been through Phase 1 (basic human safety), let alone the Phase 2 and Phase 3 efficacy trials that support an approved obesity drug. Any vendor presenting 5-Amino-1MQ as a proven fat-loss or muscle-building treatment is making a claim the human evidence cannot support, because that evidence does not exist.

Regulatory reality: an unapproved research chemical

5-Amino-1MQ has no FDA approval for any human indication and is not an approved drug product. It is generally sold online — often alongside true peptides — labeled “for research use only, not for human consumption,” a disclaimer that lets vendors ship it while sidestepping drug-marketing rules, and one that buyers routinely ignore. Because it is not a regulated medicine, no agency has verified the identity, purity, sterility, or actual dose of what is in the bottle or vial. Marketing materials lean heavily on the mouse mechanism and on before-and-after testimonials, neither of which is human clinical evidence. The practical upshot is that someone buying 5-Amino-1MQ is self-administering an unapproved compound, at an unverified dose and purity, with no medical oversight and no human safety data to fall back on.

What an evidence-backed weight-loss drug looks like

The contrast with FDA-approved obesity medications is stark. Semaglutide (Wegovy) was tested in the STEP-1 Phase-3 trial — a randomized, double-blind, placebo-controlled study in adults with overweight or obesity — and produced a mean body-weight change of about −14.9% at 68 weeks versus −2.4% for placebo^[1]. Tirzepatide (Zepbound) in the SURMOUNT-1 trial produced a mean reduction of up to −20.9% at 72 weeks^[2]. Both are large, pre-registered human randomized controlled trials with thousands of participants, published in the New England Journal of Medicine, supporting an FDA-approved indication. 5-Amino-1MQ has none of that — no Phase 1, no Phase 2, no Phase 3, no FDA review, no approved indication, and not a single published human study. If you are looking for a weight-loss treatment that actually has evidence behind it, this is the category to look in.

For a fuller map of the landscape, see our hub review of peptides for weight loss, which sorts FDA-approved peptide drugs from compounded versions and unapproved research compounds, and the companion debunker on non-GLP-1 peptides marketed for fat loss, which covers 5-Amino-1MQ alongside AOD-9604, CJC-1295/Ipamorelin, tesofensine, and cagrilintide. The shared thread across that grey-market tail is the same one here: an interesting mechanism, sometimes promising animal data, and an evidentiary gap where the human trials should be.

Bottom line

5-Amino-1MQ is a small-molecule NNMT inhibitor — not a peptide — with a genuinely interesting mouse mechanism: blocking NNMT in fat tissue raises NAD+ and SAM, suppresses lipogenesis, and reduces body weight and fat mass in diet-induced-obese mice^[3]. But that is where the evidence stops. There are no human trials of any kind, no human safety or efficacy data, and no FDA approval. It is sold as an unregulated research chemical whose contents are unverified. An interesting hypothesis in mice is a reason for scientists to run a human trial — not a reason to take an unproven compound bought online. If your goal is weight loss, the evidence points entirely toward FDA-approved medications with published human trials^[1][2] — not toward an unapproved small molecule studied so far only in mice and cells.

This article is educational and is not medical advice. Every claim above is sourced to peer-reviewed literature indexed in PubMed or to the regulatory status of the compound, verified against the live PubMed database before publication. Citations 3 through 6 are preclinical (mouse or cultured-adipocyte) NNMT-inhibitor and NNMT-biology studies; citation 3 is the foundational methylquinolinium / 5-Amino-1MQ diet-induced-obesity mouse paper. Citations 1 and 2 are human Phase-3 randomized controlled trials of FDA-approved obesity drugs, cited for contrast. Discuss any weight-loss treatment with a licensed prescriber.